BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology

  • Kim, Jongmin (Cellular Heterogeneity Research Center (CHRC), Sookmyung Women's University)
  • Received : 2017.12.30
  • Published : 2018.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

The endothelial to mesenchymal transition (EndMT) is a newly recognized, fundamental biological process involved in development and tissue regeneration, as well as pathological processes such as the complications of diabetes, fibrosis and pulmonary arterial hypertension. The EndMT process is tightly controlled by diverse signaling networks, similar to the epithelial to mesenchymal transition. Accumulating evidence suggests that microRNAs (miRNAs) are key regulators of this network, with the capacity to target multiple messenger RNAs involved in the EndMT process as well as in the regulation of disease progression. Thus, it is highly important to understand the molecular basis of miRNA control of EndMT. This review highlights the current fund of knowledge regarding the known links between miRNAs and the EndMT process, with a focus on the mechanism that regulates associated signaling pathways and discusses the potential for the EndMT as a therapeutic target to treat many diseases.

Keywords

References

  1. Michiels C (2003) Endothelial cell functions. J Cell Physiol 196, 430-443 https://doi.org/10.1002/jcp.10333
  2. Markwald RR, Fitzharris TP and Smith WN (1975) Sturctural analysis of endocardial cytodifferentiation. Dev Biol 42, 160-180 https://doi.org/10.1016/0012-1606(75)90321-8
  3. Armstrong EJ and Bischoff J (2004) Heart valve development: endothelial cell signaling and differentiation. Circ Res 95, 459-470 https://doi.org/10.1161/01.RES.0000141146.95728.da
  4. Nakajima Y, Yamagishi T, Hokari S and Nakamura H (2000) Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec 258, 119-127 https://doi.org/10.1002/(SICI)1097-0185(20000201)258:2<119::AID-AR1>3.0.CO;2-U
  5. van Meeteren LA and ten Dijke P (2012) Regulation of endothelial cell plasticity by TGF-beta. Cell Tissue Res 347, 177-186 https://doi.org/10.1007/s00441-011-1222-6
  6. Krenning G, Zeisberg EM and Kalluri R (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225, 631-637 https://doi.org/10.1002/jcp.22322
  7. Zeisberg EM, Potenta S, Xie L, Zeisberg M and Kalluri R (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67, 10123-10128 https://doi.org/10.1158/0008-5472.CAN-07-3127
  8. Ghosh AK, Quaggin SE and Vaughan DE (2013) Molecular basis of organ fibrosis: potential therapeutic approaches. Exp Biol Med (Maywood) 238, 461-481 https://doi.org/10.1177/1535370213489441
  9. Arciniegas E, Frid MG, Douglas IS and Stenmark KR (2007) Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 293, L1-L8 https://doi.org/10.1152/ajplung.00378.2006
  10. Cooley BC, Nevado J, Mellad J et al (2014) TGF-beta signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med 6, 227ra34 https://doi.org/10.1126/scitranslmed.3006927
  11. Chen PY, Qin L, Barnes C et al (2012) FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep 2, 1684-1696 https://doi.org/10.1016/j.celrep.2012.10.021
  12. Yao Y, Jumabay M, Ly A, Radparvar M, Cubberly MR and Bostrom KI (2013) A role for the endothelium in vascular calcification. Circ Res 113, 495-504 https://doi.org/10.1161/CIRCRESAHA.113.301792
  13. Chen PY, Qin L, Baeyens N et al (2015) Endothelial-tomesenchymal transition drives atherosclerosis progression. J Clin Invest 125, 4514-4528 https://doi.org/10.1172/JCI82719
  14. Maddaluno L, Rudini N, Cuttano R et al (2013) EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature 498, 492-496 https://doi.org/10.1038/nature12207
  15. Potenta S, Zeisberg E and Kalluri R (2008) The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 99, 1375-1379 https://doi.org/10.1038/sj.bjc.6604662
  16. Kovacic JC, Mercader N, Torres M, Boehm M and Fuster V (2012) Epithelial-to-mesenchymal and endothelial-tomesenchymal transition: from cardiovascular development to disease. Circulation 125, 1795-1808 https://doi.org/10.1161/CIRCULATIONAHA.111.040352
  17. Lee A, McLean D, Choi J, Kang H, Chang W and Kim J (2014) Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep 47, 311-317 https://doi.org/10.5483/BMBRep.2014.47.6.085
  18. Kim JD, Lee A, Choi J et al (2015) Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension. Exp Mol Med 47, e175 https://doi.org/10.1038/emm.2015.45
  19. Hobert O (2008) Gene regulation by transcription factors and microRNAs. Science 319, 1785-1786 https://doi.org/10.1126/science.1151651
  20. Pardali E, Sanchez-Duffhues G, Gomez-Puerto MC and Ten Dijke P (2017) TGF-beta-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. Int J Mol Sci 18
  21. Noseda M, McLean G, Niessen K et al (2004) Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res 94, 910-917 https://doi.org/10.1161/01.RES.0000124300.76171.C9
  22. Perez L, Munoz-Durango N, Riedel CA et al (2017) Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev 33, 41-54 https://doi.org/10.1016/j.cytogfr.2016.09.002
  23. Welch-Reardon KM, Wu N and Hughes CC (2015) A role for partial endothelial-mesenchymal transitions in angiogenesis? Arterioscler Thromb Vasc Biol 35, 303-308 https://doi.org/10.1161/ATVBAHA.114.303220
  24. Nagai T, Kanasaki M, Srivastava SP et al (2014) N-acetylseryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. Biomed Res Int 2014, 696475
  25. Zhang H, Hu J and Liu L (2017) MiR-200a modulates TGF-beta1-induced endothelial-to-mesenchymal shift via suppression of GRB2 in HAECs. Biomed Pharmacother 95, 215-222 https://doi.org/10.1016/j.biopha.2017.07.104
  26. Correia AC, Moonen JR, Brinker MG and Krenning G (2016) FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-beta signaling. J Cell Sci 129, 569-579 https://doi.org/10.1242/jcs.176248
  27. Sun Y, Cai J, Yu S, Chen S, Li F and Fan C (2016) MiR-630 Inhibits Endothelial-Mesenchymal Transition by Targeting Slug in Traumatic Heterotopic Ossification. Sci Rep 6, 22729 https://doi.org/10.1038/srep22729
  28. Kanasaki K, Shi S, Kanasaki M et al (2014) Linagliptinmediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63, 2120-2131 https://doi.org/10.2337/db13-1029
  29. Korpal M, Lee ES, Hu G and Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283, 14910-14914 https://doi.org/10.1074/jbc.C800074200
  30. Zhang S, Weinheimer C, Courtois M et al (2003) The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest 111, 833-841 https://doi.org/10.1172/JCI16290
  31. Ge S, Xie J, Liu F, He J and He J (2015) MicroRNA-19b reduces hepatic stellate cell proliferation by targeting GRB2 in hepatic fibrosis models in vivo and in vitro as part of the inhibitory effect of estradiol. J Cell Biochem 116, 2455-2464 https://doi.org/10.1002/jcb.25116
  32. Fafeur V, Terman BI, Blum J and Bohlen P (1990) Basic FGF treatment of endothelial cells down-regulates the 85-KDa TGF beta receptor subtype and decreases the growth inhibitory response to TGF-beta 1. Growth Factors 3, 237-245 https://doi.org/10.3109/08977199009043908
  33. Papetti M, Shujath J, Riley KN and Herman IM (2003) FGF-2 antagonizes the TGF-beta1-mediated induction of pericyte alpha-smooth muscle actin expression: a role for myf-5 and Smad-mediated signaling pathways. Invest Ophthalmol Vis Sci 44, 4994-5005 https://doi.org/10.1167/iovs.03-0291
  34. Ramos C, Becerril C, Montano M et al (2010) FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol 299, L222-231 https://doi.org/10.1152/ajplung.00070.2010
  35. Lee JG, Ko MK and Kay EP (2012) Endothelial mesenchymal transformation mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. Exp Eye Res 95, 35-39 https://doi.org/10.1016/j.exer.2011.08.003
  36. Lee HT, Lee JG, Na M and Kay EP (2004) FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J Biol Chem 279, 32325-32332 https://doi.org/10.1074/jbc.M405208200
  37. Aird WC (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100, 158-173 https://doi.org/10.1161/01.RES.0000255691.76142.4a
  38. Lagendijk AK, Goumans MJ, Burkhard SB et al (2011) MicroRNA-23 restricts cardiac valve formation by inhibiting Has2 and extracellular hyaluronic acid production. Circ Res 109, 649-657 https://doi.org/10.1161/CIRCRESAHA.111.247635
  39. Bayoumi AS, Teoh JP, Aonuma T et al (2017) MicroRNA-532 protects the heart in acute myocardial infarction, and represses prss23, a positive regulator of endothelial-to-mesenchymal transition. Cardiovasc Res 113, 1603-1614 https://doi.org/10.1093/cvr/cvx132
  40. Bijkerk R, de Bruin RG, van Solingen C et al (2012) MicroRNA-155 functions as a negative regulator of RhoA signaling in TGF-beta-induced endothelial to mesenchymal transition. Microrna 1, 2-10 https://doi.org/10.2174/2211536611201010002
  41. Ruderman NB, Williamson JR and Brownlee M (1992) Glucose and diabetic vascular disease. FASEB J 6, 2905-2914 https://doi.org/10.1096/fasebj.6.11.1644256
  42. Cao Y, Feng B, Chen S, Chu Y and Chakrabarti S (2014) Mechanisms of endothelial to mesenchymal transition in the retina in diabetes. Invest Ophthalmol Vis Sci 55, 7321-7331 https://doi.org/10.1167/iovs.14-15167
  43. Feng B, Cao Y, Chen S, Chu X, Chu Y and Chakrabarti S (2016) miR-200b Mediates Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy. Diabetes 65, 768-779 https://doi.org/10.2337/db15-1033
  44. Geng HZ and Guan J (2017) MiR-18a-5p inhibits endothelial mesenchymal transition and cardiac fibrosis through the Notch2 pathway. Biochem Biophys Res Commun 491, 329-336 https://doi.org/10.1016/j.bbrc.2017.07.101
  45. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH and Thum T (2012) Transforming Growth Factor-beta-Induced Endothelial-to-Mesenchymal Transition Is Partly Mediated by MicroRNA-21. Arterioscler Thromb Vasc Biol 32, 361-369 https://doi.org/10.1161/ATVBAHA.111.234286
  46. Ghosh AK, Nagpal V, Covington JW, Michaels MA and Vaughan DE (2012) Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT. Cell Signal 24, 1031-1036 https://doi.org/10.1016/j.cellsig.2011.12.024
  47. Suzuki HI, Katsura A, Mihira H, Horie M, Saito A and Miyazono K (2017) Regulation of TGF-beta-mediated endothelial-mesenchymal transition by microRNA-27. J Biochem 161, 417-420 https://doi.org/10.1093/jb/mvx017
  48. Li L, Kim IK, Chiasson V, Chatterjee P and Gupta S (2017) NF-kappaB mediated miR-130a modulation in lung microvascular cell remodeling: Implication in pulmonary hypertension. Exp Cell Res 359, 235-242 https://doi.org/10.1016/j.yexcr.2017.07.024
  49. Xu YP, He Q, Shen Z et al (2017) MiR-126a-5p is involved in the hypoxia-induced endothelial-to-mesenchymal transition of neonatal pulmonary hypertension. Hypertens Res 40, 552-561 https://doi.org/10.1038/hr.2017.2
  50. Kendall RT and Feghali-Bostwick CA (2014) Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 5, 123
  51. Zeisberg EM, Tarnavski O, Zeisberg M et al (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13, 952-961 https://doi.org/10.1038/nm1613
  52. Lin F, Wang N and Zhang TC (2012) The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life 64, 717-723 https://doi.org/10.1002/iub.1059
  53. He M, Chen Z, Martin M et al (2017) miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. Circ Res 120, 354-365 https://doi.org/10.1161/CIRCRESAHA.116.310233
  54. Guo Y, Li P, Bledsoe G, Yang ZR, Chao L and Chao J (2015) Kallistatin inhibits TGF-beta-induced endothelialmesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res 337, 103-110 https://doi.org/10.1016/j.yexcr.2015.06.021
  55. Shen B, Hagiwara M, Yao YY, Chao L and Chao J (2008) Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 51, 1358-1365 https://doi.org/10.1161/HYPERTENSIONAHA.107.108514

Cited by

  1. A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis vol.9, pp.1664-3224, 2018, https://doi.org/10.3389/fimmu.2018.01985
  2. No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients vol.17, pp.1, 2018, https://doi.org/10.1186/s12933-018-0715-y
  3. lncRNA H19 prevents endothelial–mesenchymal transition in diabetic retinopathy vol.62, pp.3, 2019, https://doi.org/10.1007/s00125-018-4797-6
  4. The Role of Angiogenesis and Pro-Angiogenic Exosomes in Regenerative Dentistry vol.20, pp.2, 2019, https://doi.org/10.3390/ijms20020406